PharmaCyte Biotech 2026: Revenue $0 Net income ($5.79M), EPS ($0.54) — 10-Q Summary
PharmaCyte Biotech, Inc. reported results for the 2026 quarter with revenue of $0 and a net loss of ($5.79M), or diluted loss per share of ($0.54), compared with a net loss of ($8.36M) and diluted loss per share of ($1.23) in the prior-year quarter.Financial Highlights¹ Reported as “Revenue”. ² Rep…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.